Antileprosy drugs, pregnancy and fetal outcome.
Bhargava
P
P
Kuldeep
C M
CM
Mathur
N K
NK
D000014:Abnormalities, Drug-Induced; D000293:Adolescent; D000328:Adult; D000818:Animals; D002991:Clofazimine / Q000009:adverse effects / Q000627:therapeutic use; D003622:Dapsone / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007917:Leprostatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy*; D051379:Mice; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011256:Pregnancy Outcome; D051381:Rats; D012189:Retrospective Studies; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use
D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin